Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Johnson & Johnson, Pfizer, Roche Holding unit Genentech and Sanofi will contribute financial resources and personnel to the TransCelerate Biopharma project to overcome inefficiency in drug development. The collaboration's initial focus is streamlining and standardizing clinical trials. "This collaborative approach in the precompetitive arena, utilizing the collective experience and resources of 10 leading drug companies and others to follow, has the promise to lead to new paradigms and cost savings in drug development," FDA Center for Drug Evaluation and Research Director Dr. Janet Woodcock said.
Drugmakers collaborate to overcome obstacles in R&D
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|